C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy (Q30274884)

8 July 2018

title

C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy (English)

1 reference

8 July 2018

author

Allison Lesher Williams

object named as

Allison Lesher Williams

1

0 references

author name string

Damodar Gullipalli

2

1 reference

8 July 2018

Yoshiyasu Ueda

3

1 reference

8 July 2018

Sayaka Sato

4

1 reference

8 July 2018

Lin Zhou

5

1 reference

8 July 2018

Takashi Miwa

6

1 reference

8 July 2018

Kenneth S Tung

7

1 reference

8 July 2018

Wen-Chao Song

8

1 reference

8 July 2018

language of work or name

English

0 references

publication date

27 January 2017

1 reference

8 July 2018

published in

Kidney International

1 reference

8 July 2018

volume

91

1 reference

8 July 2018

issue

6

1 reference

8 July 2018

page(s)

1386-1397

1 reference

8 July 2018

Diagnosis of complement alternative pathway disorders

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab in Pediatric Dense Deposit Disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

C3 glomerulopathy: consensus report

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Diagnosis and treatment of C3 glomerulopathy.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Properdin in complement activation and tissue injury

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab and recurrent C3 glomerulonephritis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Recent insights into C3 glomerulopathy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Pathology after eculizumab in dense deposit disease and C3 GN.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab and Refractory Membranoproliferative Glomerulonephritis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab for the Treatment of Dense-Deposit Disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab in a patient with dense-deposit disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Eculizumab for dense deposit disease and C3 glomerulonephritis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Causes of alternative pathway dysregulation in dense deposit disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

14 July 2018

Dense deposit disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

C3 glomerulopathy: a new classification

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

New approaches to the treatment of dense deposit disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Structure/function of C5 convertases of complement

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

The C5a chemoattractant receptor mediates mucosal defence to infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

The role of properdin in the alternate pathway of complement activation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Effectiveness of mycophenolate mofetil in C3 glomerulonephritis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429978

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies

26 November 2018

1 reference

12 December 2020

Eculizumab for treatment of rapidly progressive C3 glomerulopathy

1 reference

12 December 2020

Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF

1 reference

12 December 2020

Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up

1 reference

12 December 2020

Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies

1 reference

12 December 2020

Eculizumab in the treatment of membranoproliferative glomerulonephritis

1 reference

12 December 2020

10.1016/J.KINT.2016.11.018

Identifiers

DOI

1 reference

8 July 2018

PMC publication ID

5429978

1 reference

8 July 2018

PubMed publication ID

28139294

1 reference

8 July 2018